Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis - Wikidata - awgldk - TriplyDB

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

http://www.wikidata.org/entity/Q27000819

about

Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement Autoantibodies in systemic sclerosis: unanswered questions Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody.Treatment of systemic sclerosis: is there any hope for the future?Scleroderma renal crisis and renal involvement in systemic sclerosis.Personalized medicine in rheumatology: the paradigm of serum autoantibodies.Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study.Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.Systemic sclerosis and the gastrointestinal tract.Disease-related autoantibody profile in patients with systemic sclerosis.Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?Reply: To PMID 25512203.Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis

P2860

Q26995764-82FE4461-8494-4065-98E7-EC67D3BBA708 Q28085026-957C070A-9873-414F-BF23-519E226ED4FA Q28088499-A41FDCD0-6150-4CDB-936A-3DFDC8BE986B Q36040200-DA291D33-AEDF-466B-AD67-63F21617EFCD Q36129874-09CEEDFD-3103-4902-BC50-E5E6A28697B0 Q37660988-C1D27FC7-D6F9-4354-A0D1-846C0F43C908 Q38834999-F93036C4-8226-4DC2-8B78-CDA244BF6C5A Q38957950-E0C87225-9F6A-4261-B646-5B8E3E032F7B Q39432157-69989466-6567-4C5D-B3DD-0FFC45349B10 Q39493821-7085EBCB-1805-42DC-99A5-F89AB09C7442 Q40656308-4BDCA646-2711-4711-823D-D11CC311D297 Q47100435-C264CEF2-2644-4F2D-998A-90F6D3109DF6 Q47685250-ED33E7BD-D918-49C0-8DE6-E2386675ED58 Q52597638-476CC434-760C-4545-944F-2F4AA4CAD2C4 Q54271316-320EDA0B-185C-45C8-AAB1-EDA1856B6129 Q59125590-ACE80017-BC5B-41D5-B41A-93CAFE72DF9D

P2860

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

http://www.wikidata.org/entity/Q27000819

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@ast

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@en

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@nl

type

label

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@ast

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@en

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@nl

prefLabel

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@ast

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@en

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@nl

P1433

Q27000819-87806985-9BD3-4CF4-8305-85EE88B4C301

P1476

Q27000819-C3D0E408-25BA-4C51-99D3-2E72BFF62C63

P2093

Q27000819-EB4E715A-1D05-45AD-861B-F4220144C194

Q27000819-EE75F6B2-64F3-4FCB-97D5-232BCFA8598B

Q27000819-F3E3CBC4-212C-4BB8-B787-0A15E1301B1D

P2860

Q27000819-0BAB3652-BA93-4B26-B937-52E3C824CD44

Q27000819-0C5A7A2E-540B-4361-A695-C767A218AC05

Q27000819-0FE31474-0A7E-4E3F-B733-F48CA2D3570D

Q27000819-1303995B-E023-4A9C-8697-E5196EB7841C

Q27000819-1C0ACD3B-A6F3-44FA-BD49-20CEDA0BC584

Q27000819-2B936A13-53C0-449F-B3E6-D673D4EEA7DE

Q27000819-33FE7041-FE7F-4A93-93D2-872B931EDF0E

Q27000819-3746D4C8-DDEA-4178-BF71-C74A2EEB1BF6

Q27000819-3F5D1E9E-C52C-4D11-B1E6-16787AB1DB87

Q27000819-418A2B24-CD9D-49B5-94FB-E83460AD4B57

P304

Q27000819-4F8CCED2-86F0-4787-B9D6-FD9F81654D20

P31

Q27000819-B799759B-FE7E-40D1-8B07-A80E392CBF61

Q27000819-C5E8B8E6-33DB-4559-916A-C5E7E8962DD0

Q27000819-D9EE64E5-3805-4425-8DA4-BB41F48D8ADC

P3181

Q27000819-177CEA19-E155-4AE5-AC87-A2494BAED917

P356

Q27000819-E885C2C7-9307-4624-8689-7A41A84D7873

P407

Q27000819-1B94AAD2-81DA-4B73-81FA-B155DB29E187

P433

Q27000819-EA2EBA5A-B123-408D-BE66-B98F3FFF19E1

P478

Q27000819-11C8126B-4CEE-4891-93B0-E70EDD4A2DD2

P50

Q27000819-3726C9A0-F3E0-4717-A6DD-85CD17AA959B

Q27000819-54130ED1-583D-4BCB-8C42-EE72CC6C8972

Q27000819-5DF905E5-163C-4624-A1F0-28E0468AE4AD

Q27000819-A068F4E7-95EA-4107-84E8-B2D203BE21E6

Q27000819-C654129E-036C-4DA0-A59F-AE72D93806BF

Q27000819-D000530D-D958-4E82-BF67-CCE58964C607

Q27000819-E56AADD2-D23A-4C60-BA26-44FCE19222BB

P577

Q27000819-D6E8CF57-A44F-4405-AD5B-7F16DDC67D96

P5875

Q27000819-B525AD09-11E8-4F80-B204-A364B12C123C

P698

Q27000819-356EF1FE-31E0-46D1-8168-791D3FBFFC26

P921

Q27000819-6A413820-7EAC-4F8E-8120-506C745D6F61

Q27000819-AEC15E6A-87A7-48F6-A3EF-8E970BF1AAB8

P3181

P356

P1433

Arthritis & Rheumatology

P1476

Prevalence of anti-RNA polymer ...... matic review and meta-analysis

@en

P2093

Pierre-Yves Hatron

http://www.w3.org/2001/XMLSchema#string

Sandrine Morell-Dubois

http://www.w3.org/2001/XMLSchema#string

Thierno Sy

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay

Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis

Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis.

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

Scleroderma renal crisis: patient characteristics and long-term outcomes.

Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.

Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features

P304

407-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

3575317

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.38219

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Sylvain Dubucquoi

Vincent Sobanski

Guillaume Lefevre

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260121365

http://www.w3.org/2001/XMLSchema#string

P698

24504813

http://www.w3.org/2001/XMLSchema#string

P921